These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 20806940)

  • 21. High-resolution structure of HLA-A*0201 in complex with a tumour-specific antigenic peptide encoded by the MAGE-A4 gene.
    Hillig RC; Coulie PG; Stroobant V; Saenger W; Ziegler A; Hülsmeyer M
    J Mol Biol; 2001 Jul; 310(5):1167-76. PubMed ID: 11502003
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma.
    Romero P; Valmori D; Pittet MJ; Zippelius A; Rimoldi D; Lévy F; Dutoit V; Ayyoub M; Rubio-Godoy V; Michielin O; Guillaume P; Batard P; Luescher IF; Lejeune F; Liénard D; Rufer N; Dietrich PY; Speiser DE; Cerottini JC
    Immunol Rev; 2002 Oct; 188():81-96. PubMed ID: 12445283
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Culture of melanoma cells in 3-dimensional architectures results in impaired immunorecognition by cytotoxic T lymphocytes specific for Melan-A/MART-1 tumor-associated antigen.
    Ghosh S; Rosenthal R; Zajac P; Weber WP; Oertli D; Heberer M; Martin I; Spagnoli GC; Reschner A
    Ann Surg; 2005 Dec; 242(6):851-7, discussion 858. PubMed ID: 16327495
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6.
    Maeurer MJ; Gollin SM; Storkus WJ; Swaney W; Karbach J; Martin D; Castelli C; Salter R; Knuth A; Lotze MT
    Clin Cancer Res; 1996 Apr; 2(4):641-52. PubMed ID: 9816214
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diversity of the fine specificity displayed by HLA-A*0201-restricted CTL specific for the immunodominant Melan-A/MART-1 antigenic peptide.
    Valmori D; Gervois N; Rimoldi D; Fonteneau JF; Bonelo A; Liénard D; Rivoltini L; Jotereau F; Cerottini JC; Romero P
    J Immunol; 1998 Dec; 161(12):6956-62. PubMed ID: 9862730
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.
    Di Pucchio T; Pilla L; Capone I; Ferrantini M; Montefiore E; Urbani F; Patuzzo R; Pennacchioli E; Santinami M; Cova A; Sovena G; Arienti F; Lombardo C; Lombardi A; Caporaso P; D'Atri S; Marchetti P; Bonmassar E; Parmiani G; Belardelli F; Rivoltini L
    Cancer Res; 2006 May; 66(9):4943-51. PubMed ID: 16651452
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating Melan-A/Mart-1 specific cytolytic T lymphocyte precursors in HLA-A2+ melanoma patients have a memory phenotype.
    D'Souza S; Rimoldi D; Líenard D; Lejeune F; Cerottini JC; Romero P
    Int J Cancer; 1998 Dec; 78(6):699-706. PubMed ID: 9833762
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Conformational changes within the HLA-A1:MAGE-A1 complex induced by binding of a recombinant antibody fragment with TCR-like specificity.
    Kumar P; Vahedi-Faridi A; Saenger W; Ziegler A; Uchanska-Ziegler B
    Protein Sci; 2009 Jan; 18(1):37-49. PubMed ID: 19177349
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Crystallization and preliminary X-ray structural studies of a Melan-A pMHC-TCR complex.
    Yuan F; Georgiou T; Hillon T; Gostick E; Price DA; Sewell AK; Moysey R; Gavarret J; Vuidepot A; Sami M; Bell JI; Gao GF; Rizkallah PJ; Jakobsen BK
    Acta Crystallogr Sect F Struct Biol Cryst Commun; 2007 Sep; 63(Pt 9):758-60. PubMed ID: 17768347
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective responsiveness to common gamma chain cytokines in peripheral blood-derived cytotoxic T lymphocytes induced by Melan-A/MART-1(27-35)targeted active specific immunotherapy.
    von Holzen U; Adamina M; Bolli M; Weber WP; Zajac P; Groeper C; Reschner A; Feder C; Schumacher R; Marti W; Oertli D; Heberer M; Spagnoli GC
    Int J Cancer; 2005 Jun; 115(2):248-55. PubMed ID: 15688403
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35).
    Loftus DJ; Castelli C; Clay TM; Squarcina P; Marincola FM; Nishimura MI; Parmiani G; Appella E; Rivoltini L
    J Exp Med; 1996 Aug; 184(2):647-57. PubMed ID: 8760818
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel soluble HLA-A2/MELAN-A complexes selectively stain a differentiation defective subpopulation of CD8+ T cells in patients with melanoma.
    Guillaume P; Baumgaertner P; Neff L; Rufer N; Wettstein P; Speiser DE; Luescher IF
    Int J Cancer; 2010 Aug; 127(4):910-23. PubMed ID: 19998338
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Schmidt J; Guillaume P; Dojcinovic D; Karbach J; Coukos G; Luescher I
    J Biol Chem; 2017 Jul; 292(28):11840-11849. PubMed ID: 28536262
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phosphorylation-dependent interaction between antigenic peptides and MHC class I: a molecular basis for the presentation of transformed self.
    Mohammed F; Cobbold M; Zarling AL; Salim M; Barrett-Wilt GA; Shabanowitz J; Hunt DF; Engelhard VH; Willcox BE
    Nat Immunol; 2008 Nov; 9(11):1236-43. PubMed ID: 18836451
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Subcellular localization of the melanoma-associated protein Melan-AMART-1 influences the processing of its HLA-A2-restricted epitope.
    Rimoldi D; Muehlethaler K; Salvi S; Valmori D; Romero P; Cerottini JC; Levy F
    J Biol Chem; 2001 Nov; 276(46):43189-96. PubMed ID: 11551907
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
    Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
    Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions.
    Anichini A; Molla A; Mortarini R; Tragni G; Bersani I; Di Nicola M; Gianni AM; Pilotti S; Dunbar R; Cerundolo V; Parmiani G
    J Exp Med; 1999 Sep; 190(5):651-67. PubMed ID: 10477550
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Large-scale molecular dynamics simulations of HLA-A*0201 complexed with a tumor-specific antigenic peptide: can the alpha3 and beta2m domains be neglected?
    Wan S; Coveney P; Flower DR
    J Comput Chem; 2004 Nov; 25(15):1803-13. PubMed ID: 15386470
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TCRs used in cancer gene therapy cross-react with MART-1/Melan-A tumor antigens via distinct mechanisms.
    Borbulevych OY; Santhanagopolan SM; Hossain M; Baker BM
    J Immunol; 2011 Sep; 187(5):2453-63. PubMed ID: 21795600
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells.
    Zarour HM; Kirkwood JM; Kierstead LS; Herr W; Brusic V; Slingluff CL; Sidney J; Sette A; Storkus WJ
    Proc Natl Acad Sci U S A; 2000 Jan; 97(1):400-5. PubMed ID: 10618430
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.